《大行報告》富瑞上調世茂(00813.HK)目標價至5.81元 評級「持有」
世茂集團(00813.HK)向國企上海地產(集團),出售位於上海虹口區外灘名為「上海外灘茂悅大酒店」,代價45億人民幣。富瑞發表報告,預計世茂將繼續剝離其核心資產,將在短期內降低其違約風險,但也會抑制其中期銷售和盈利前景,可能需時數年才能恢復。該行將其目標價由4.92元上調至5.81元,維持評級「持有」。
由於項目交付延遲和毛利率下降,富瑞將世茂2021年盈利預測下調11%,毛利率預測下調至約26%,意味著盈利按年下降18%,但將2022至2023盈利預測上調 6%至8%至約115億元人民幣,以反映出售收益入帳。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.